Diro EGJ, Lynen L, Ritmeijer KKD, Boelaert M, Hailu ADE, et al.
2014-06-26 • PLOS Neglected Tropical Diseases
2014-06-26 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload a...
Wassuna M, Njenga SN, Balasegaram M, Alexander N, Omollo R, et al.
2016-09-14 • PLOS Neglected Tropical Diseases
2016-09-14 • PLOS Neglected Tropical Diseases
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBis...
To develop a method for determining the acceptability and safety of ready-to-use therapeutic foods (RUTF) before clinical trialing. Acceptability was defined using a combination of three...
BACKGROUND Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Hailu ADE, Musa AM, Wasunna M, Balasegaram M, Yifru S, et al.
2010-10-26 • PLOS Neglected Tropical Diseases
2010-10-26 • PLOS Neglected Tropical Diseases
Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is in...
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Diro EGJ, Ritmeijer KKD, Boelaert M, Alves F, Mohammed R, et al.
2017-09-13 • Clinical Infectious Diseases
2017-09-13 • Clinical Infectious Diseases
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 m...
Kimutai R, Musa AM, Njoroge SM, Omollo R, Alves F, et al.
2017-03-01 • Clinical Drug Investigation
2017-03-01 • Clinical Drug Investigation
INTRODUCTION In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscu...
van Griensven J, Diro EGJ, Lopez-Velez R, Ritmeijer KKD, Boelaert M, et al.
2014-08-07 • PLOS Neglected Tropical Diseases
2014-08-07 • PLOS Neglected Tropical Diseases
In the wake of the HIV epidemic, visceral leishmaniasis (VL), a disseminated protozoan infection caused by the Leishmania donovani complex, has been re-emerging, particularly in North Et...
